培妥莫单抗
| 单克隆抗体 | |
|---|---|
| 种类 | ? |
| 目標 | MUC1 |
| 臨床資料 | |
| 商品名 | Theragyn |
| 给药途径 | 腹膜给药 |
| ATC碼 |
|
| 识别信息 | |
| CAS号 | 646032-04-4  |
| ChemSpider |
|
培妥莫单抗（INN：pemtumomab；商品名：Theragyn），或译潘妥莫单抗，是一种用于治疗癌症的小鼠单克隆抗体。该药物通过多态性上皮黏蛋白（PEM或MUC1）对多种类型的癌症（例如卵巢癌和腹膜癌）具有亲和力，并将放射性同位素钇-90输送到肿瘤中。[1]截至2009年，它正在进行III期临床试验。[2]
参考资料
- ^ Oei AL, Moreno M, Verheijen RH, Sweep FC, Thomas CM, Massuger LF, von Mensdorff-Pouilly S. Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer. International Journal of Cancer. October 2008, 123 (8): 1848–53. PMID 18661524. S2CID 2287723. doi:10.1002/ijc.23725
.
- ^ Clinical trial number NCT00004115 for "Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy" at ClinicalTrials.gov
- ^ Antisoma's Lead Product, Pemtumomab Granted European Orphan Drug Status[失效連結]
